|
| |
| | Definition of Carboplatin |
 | | Carboplatin is a clinically used anticancer drug against some form of cancers. | | | Carboplatin differs from cisplatin in that it has a closed cyclobutane dicarboxylate (CBDCA) moiety on its leaving arm in contrast to the readily leaving chloro groups. | | | Two theories exist to explain the molecular mechanism of action of carboplatin with DNA. |
|
http://www.wordiq.com/definition/Carboplatin
|
|
| |
| | MedlinePlus Drug Information: Carboplatin (Systemic) |
| | Carboplatin is to be administered only by or under the immediate supervision of your doctor. | | | Before you begin treatment with carboplatin, you and your doctor should talk about the good this medicine will do as well as the risks of using it. | | | While you are being treated with carboplatin, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. |
|
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202115.html
|
|
| |
| | Carboplatin: BC Cancer Agency |
| | Peripheral neuropathy is more common in patients over 65, receiving prolonged carboplatin therapy or with prior cisplatin therapy. | | | Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. | | | Patients with pre-existing cisplatin-induced peripheral neurotoxicity generally do not worsen during carboplatin therapy. |
|
http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Carboplatin1of2
|
|
| |
| | CancerBACUP : Carboplatin (Paraplatin) |
| | Tiredness and a general feeling of weakness It is important to allow yourself plenty of time to rest. | | | If you have any further questions you can ask your doctor or nurse at the hospital where you are having your treatment, or speak to one of CancerBACUP's Cancer Support Service nurses. | | | Let your doctor know if you have any unexplained bruising or bleeding. |
|
http://www.cancerbacup.org.uk/info/carboplatin.htm
|
|
| |
| | Carboplatin: Mesothelioma Cancer Treatment |
| | It should be clearly understood by the patient, that his or her ability to conceive or father a child may be affected by taking Carboplatin. | | | Patients should avoid taking other medicines while undergoing chemotherapy, unless they are granted their doctor's approval to do so. | | | Less commonly, they may experience numbness or tingling in hands or feet, changes in hearing (tinnitus), diarrhea, mouth sores and ulcers, and/or hair loss. |
|
http://www.mesothelioma-cancer-treatment.com/pages/carboplatin.html
|
|
| |
| | Chemotherapy for Non-small Cell Lung Cancer - September 2001: 709581 |
| | This should increase the possibility of application of individualized therapy and, we would hope, improve survival. | | | Whether three-drug combinations including docetaxel will result in an improved outcome for patients with advanced NSCLC remains to be determined. | | | Docetaxel also produced a significant 1-year survival rate improvement when compared with vinorelbine or ifosfamide as second-line therapy. |
|
http://www.acor.org/cnet/709581.html
|
|
| |
| | Weekly Paclitaxel Plus Carboplatin Safe and Effective for Lung Cancer Patients--Press Release |
| | The study presented enrolled 390 patients with previously untreated advanced and metastatic NSCLC to determine which of three weekly regimens of induction paclitaxel plus carboplatin was the most safe and effective. | | | After receiving 16 weeks of this induction therapy on all three arms, patients who experienced either a complete or partial response or stable disease were further randomized to maintenance weekly paclitaxel (70 mg/m2) vs. observation. | | | Also, only five percent of patients receiving weekly paclitaxel plus carboplatin experienced grade 3-4 neuropathy. |
|
http://www.upci.upmc.edu/news/upci_news/2001/052101_lung_drug.html
|
|
| |
| | MedlinePlus Drug Information: Carboplatin |
| | Talk to your doctor about the possible risks of using this drug for your condition. | | | This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information. | | | tell your doctor and pharmacist if you are allergic to carboplatin (Paraplatin) or any other platinum-containing compound such as cisplatin (Platinol, CDDP) or any other drugs. |
|
http://www.cheap-xenical.com/Ca/a695017.html
|
|
| |
| | Carboplatin factsheet |
| | This fact sheet explains what Carboplatin is, how it is given and some of the possible side effects. | | | Your child will have a hearing test before and during the course of treatment and at long-term follow up clinics. | | | This is temporary and the hair will grow back once the treatment has finished. |
|
http://www.gosh.nhs.uk/factsheets/families/F000240/index.html
|
|
| |
| | First Evidence of Otoprotection Against Carboplatin-Induced Hearing Loss with a Two-Compartment System in Patients with ... |
| | A series of audiograms from the right ear of a single representative patient were obtained before initiating brain tumor therapy (5/15/96) and at monthly intervals before the next treatment with BBBD and carboplatin followed by STS (6/10/96, 7/8/96). | | | A series of audiograms from the right ear of a single representative patient were obtained before initiating brain tumor therapy (base line, 10/12/93) and at monthly intervals before the next treatment with BBBD and carboplatin (11/8/93, 12/8/93, 1/12/94, 2/9/94). | | | Patients treated with high-dose STS from the beginning of their BBBD plus carboplatin therapy |
|
http://www.jpet.org/cgi/content/full/286/1/77
|
|
| |
| | Lung Cancer, Non-Small Cell |
| | The purpose of this study is to determine the response rate (RR) and toxicity associated with neoadjuvant therapy (NAT) using carboplatin (AUC 7) and paclitaxel (200 mg/M | | | Further follow-up is planned allowing an analysis on 618 patients. | | | The response and one year survival rate from this regimen is encouraging. |
|
http://www.rosoncoweb.ru/cure/taxol/thes22.htm
|
|
| |
| | ASCO - Browse by Meeting - Abstracts in Category |
| | Phase II Study of Induction Carboplatin (CAR) and Docetaxel (DOC) with Concurrent Thoracic Radiation (CTRT) Followed by Surgical Resection in Stage IB, IIA and IIB Non-Small Cell Lung Cancer (NSCLC). | | | Outcome of Patients Receiving Radiation Therapy (RT) for Stage I-III Non Small-Cell Lung Cancer (NSCLC): Results of the 1995-1997 Patterns of Care Study (PCS) in Japan. | | | Combination of Docetaxel and Carboplatin as Second-Line Treatment in Patients (Pts) with Advanced Non-Small-Cell Lung Cancer (NSCLC). |
|
http://www.asco.org/ac/1,1003,_12-002626-00_18-0010-00_19-00348,00.asp
|
|
| |
| | News - Bevacizumab When Added to Paclitaxel Plus Carboplatin Improves Survival in Advanced Nonsquamous Non-Small-Cell ... |
| | The standard chemotherapy approach of paclitaxel plus carboplatin in combination with a range of new targeted therapies have all proven negative, said Alan B. Sandler, MD, principal investigator and associate professor, department of hematology and oncology, Vanderbilt-Ingram Cancer Centre, Nashville, Tennessee. | | | The researchers thus looked to the development of a new target; "Angiogenesis is another pathway that we can consider, with tumor growth being dependent on angiogenesis, which itself is highly dependent upon the VEGF pathway," said Dr Sandler. | | | The researchers randomized 444 patients to receive paclitaxel 200 mg/m |
|
http://www.docguide.com/news/content.nsf/news/8525697700573E18852570350046AB04
|
|
| |
| | combination of taxol and carboplatin |
| | This combination was reported at the 23rd annual San Antonio Breast Cancer Symposium in December, 2000 by Dr. David Loesch, MD the lead investigator of this study. | | | I am sorry the 5FU and Lukovorin has stopped working but there ARE other drugs. | | | There were relatively low side effects in patients treated with taxol and carboplatin.” In this study the taxol and carboplatin were given on a weekly basis. |
|
http://www.medhelp.org/forums/BreastCancer/messages/27a.html
|
|
| |
| | ACS :: Cancer Drug Guide: carboplatin |
| | Your doctor or nurse will give you specific instructions if your blood counts are low. | | | You will probably get an antinausea drug before receiving this medicine. | | | While you are being treated with carboplatin, and after you stop treatment, do not have any immunizations (vaccinations) without your doctor’s okay. |
|
http://www.cancer.org/docroot/CDG/content/CDG_carboplatin.html
|
|
| |
| | Chemotherapy for Non-small Cell Lung Cancer - July 2001: 707581 |
| | Randomised studies indicate symptomatic relief and improvement of indices of quality of life (QoL) for patients who receive platinum-based combination chemotherapy or single drug therapy with more recent compounds. | | | CONCLUSION: The combination of gemcitabine and docetaxel with prophylactic use of rhG-CSF is a safe and well-tolerated regimen for the treatment of patients with advanced NSCLC, who failed front-line treatment with cisplatin-based regimens. | | | Two patients had received cisplatin and CPT-11, one patient had received weekly paclitaxel, and one patient had received carboplatin and docetaxel. |
|
http://www.acor.org/cnet/707581.html
|
|
| |
| | Drug Prevents Hearing Loss Caused By Brain Tumor Therapy |
| | The VA/OHSU team eventually confirmed that STS could preserve hearing in animals treated with carboplatin (Cancer Research, February 15, 1996) and proceeded with clinical trials. | | | The related drug carboplatin, however, previously had caused only modest hearing loss when used to treat patients with cancers in other parts of the body. | | | These patients had an average hearing loss of 20.8 decibels after one treatment with carboplatin, while the STS-treated patients lost only 3.7 decibels. |
|
http://www.eurekalert.org/pub_releases/1998-07/OHSU-DPHL-070798.php
|
|
| |
| | Carboplatin Health Web Links |
| | Avoid having your ego so close to your position that when your position falls, your ego goes with it. | | | :: Health :: :: Pharmacy :: :: Drugs and Medications :: :: C :: :: Carboplatin :: | | | Carboplatin - FamilyDoctor.org - Information for patients in English or Spanish. |
|
http://www.internet-health-directory.com/Pharmacy_Drugs_and_Medications_C_Carboplatin.html
|
|
| |
| | Carboplatin dose clearance calculator Area under the curve AUC. |
| | Gleevec as first line therapy in CML found to be beneficial | | | For obese patients : if total body weight (TBW)/ ideal body weight (IBW) >= 1.2, weight is corrected by the mean between TBW and IBW. | | | Get started here by becoming a member of The Doctors Lounge. |
|
http://www.thedoctorslounge.net/calc/carboplatinauc.htm
|
|
| |
| | Chemotherapy w Antioxidants |
| | Remember we are NOT Doctors and have NO medical training. | | | Growth inhibition and induction of apoptosis was studied by morphological changes, MTT assay and flow-cytometric analysis. | | | In this study, the objective was to see whether pretreatment with antioxidant mixture could enhance the cytotoxic and apoptotic effect of commonly used chemotherapeutic agents, paclitaxel and carboplatin for the treatment of NSCLC. |
|
http://www.annieappleseedproject.org/chemwan.html
|
|
| |
| | Carboplatin |
| | This leaflet, aimed at parents, provides information about carboplatin, a chemotherapy drug that is used to treat certain types of cancer. | | | It explains how the drug is given, and the side effects. | | | Patient Education Handout [Publication Type] ; Child ; Carboplatin ; |
|
http://www.omni.ac.uk/browse/mesh/D016190.html
|
|
| |
| | Drug Combo Effective For Advanced Breast Cancer |
| | Lead by researchers Dr. Dennis Slamon and Dr. Mark Pegram, the laboratory studies analyzed Herceptin for interaction with nine chemotherapy drugs commonly used to treat breast cancer. | | | Responses — shrinkage in tumor size — were observed in 79 percent of patients in one of the studies and in 58 percent of patients in the other. | | | In two Phase II clinical trials, Taxotere was given with Herceptin in combination with either Cisplatin or Carboplatin to women who tested positive for the HER2/neu alteration. |
|
http://www.sciencedaily.com/releases/2004/05/040519065148.htm
|
|
| |
| | OncoLink Libraryâ”Cancer Journals, Cancer Books, Cancer Poetry |
| | Therefore, carboplatin plus paclitaxel is considered the preferred regimen for patients with ovarian cancer. | | | Although carboplatin and paclitaxel may now represent the standard of adjuvant chemotherapy in patients with ovarian cancer, obviously further investigations are required to improve on these outcomes. | | | Though this may affect the outcomes, it also speaks to the fact that patients can tolerate higher doses with carboplatin. |
|
http://www.oncolink.upenn.edu/library/article.cfm?c=2&s=40&id=741
|
|
| |
| | National Cancer Institute - Clinical Trials (PDQ®) |
| | Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Treating Patients With Stage III Non-small Cell Lung Cancer | | | Compare the survival and time to progression of patients with stage IIIA or IIIB non-small cell lung cancer when treated with carboplatin, paclitaxel, and chemoradiotherapy with or without thalidomide. | | | Phase III Randomized Study of Carboplatin, Paclitaxel, and Chemoradiotherapy With or Without Thalidomide in Patients With Stage III Non-Small Cell Lung Cancer |
|
http://cancer.gov/clinicaltrials/ECOG-3598
|
|
| |
| | XYOTAX in Combination with Carboplatin Produces Major Tumor Response in 98 Percent of First-line Ovarian Cancer ... |
| | The study was designed to evaluate the toxicity and efficacy of XYOTAX in combination with carboplatin as an induction therapy followed by single-agent XYOTAX as monthly maintenance therapy in patients with newly diagnosed stage III or IV ovarian cancer. | | | Of the 82 patients studied, 80 patients (98 percent) achieved a major tumor response (CR+PR based on reduction in CA-125 levels) during the induction phase of the therapy, 85 percent complete response (CR) and 12 percent partial response (PR). | | | Grade 3/4 side effects at the 175mg/m2 dose in combination with carboplatin (AUC=6) included neuropathy (23 percent), nausea (15 percent), vomiting (7 percent), febrile neutropenia (19 percent), anemia (11 percent), and thrombocytopenia (55 percent). |
|
http://www.forbes.com/prnewswire/feeds/prnewswire/2005/05/14/prnewswire200505141527PR_NEWS_B_MAT_NY_NYSA014.html
|
|
| |
| | Articles |
| | Single-agent carboplatin and CAP are as effective as paclitaxel plus carboplatin as first-line treatment for women requiring chemotherapy for ovarian cancer. | | | The favourable toxicity profile of single-agent carboplatin suggests that this drug is a reasonable option as first-line chemotherapy for ovarian cancer. | | | Women were randomly assigned paclitaxel plus carboplatin or control, the control (CAP or single-agent carboplatin) being chosen by the patient and clinician before randomisation. |
|
http://www.weisenthal.org/icon_3.htm
|
|
| |
| | National Cancer Institute - Clinical Trials (PDQ®) |
| | Determine the complete response in patients treated with these regimens. | | | Determine the activity of cisplatin or carboplatin in combination with gemcitabine, in terms of response rate, in patients with locally advanced, recurrent, or metastatic malignant salivary gland tumor. | | | No other serious illness or medical condition that would preclude study participation |
|
http://cancer.gov/clinicaltrials/CAN-NCIC-HN4
|
|
| |
| | The United Kingdom Children's Cancer Study Group's Second Germ Cell Tumor Study: Carboplatin, Etoposide, and Bleomycin ... |
| | Horwich A, Sleijfer D, Fossa S, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. | | | The United Kingdom Children’s Cancer Study Group’s Second Germ Cell Tumor Study: Carboplatin, Etoposide, and Bleomycin Are Effective Treatment for Children With Malignant Extracranial Germ Cell Tumors, With Acceptable Toxicity | | | Carboplatin is more myelotoxic than cisplatin, and myelotoxicity |
|
http://www.jco.org/cgi/content/full/18/22/3809
|
|
| |
| | Variations In DNA Repair Genes May Predict Survival In Non-small Cell Lung Cancer Patients |
| | Alexandria, VA -- Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows. | | | The findings, if verified in larger studies, may help oncologists tailor chemotherapy to patients based on their genetic make-up. | | | Study investigators evaluated genetic variations (also called polymorphisms) in two DNA repair genes — XPD and XRCC1 — in 103 patients diagnosed with stage III or IV non-small cell lung cancer who were treated with cisplatin or carboplatin. |
|
http://www.sciencedaily.com/releases/2004/06/040602063128.htm
|
|
| |
| | Definition of carboplatin |
| | Carboplatin interferes with the growth of cancer cells. | | | A brand name is Paraplatin, made by Bristol-Meyers Squibb. |
|
http://www.phoenix5.org/glossary/carboplatin.html
|
|
| |
| | A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor ... |
| | A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience | | | A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities -- Bracho et al. | | | A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities |
|
http://clincancerres.aacrjournals.org/cgi/content/full/7/1/58
|
|
|
